Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194037 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
A Phase 1 study of Chronic Hepatitis C Infection and Genotype 1, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT01194037 is a Phase 1 study of Chronic Hepatitis C Infection and Genotype 1 that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 30 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT01194037, a Phase 1 study of Chronic Hepatitis C Infection and Genotype 1, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG Peginterferon alfa-2a
- DRUG recombinant variant of interferon-alpha 2b
Study Locations (6)
California
- - Los Angeles
- - National City
Florida
- - Miami
Georgia
- - Atlanta
Kentucky
- - Lexington
Louisiana
- - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06-23 |
| Est. Completion | 2011-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194037
The ClinicalTrials.gov registry entry for NCT01194037 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HanAll BioPharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Hepatitis C Infection appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT01194037 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01194037 about?
NCT01194037 is a clinical study titled "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C". This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
What is the current status of trial NCT01194037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-06-23. Estimated completion is 2011-11-28.
What conditions does trial NCT01194037 study?
This clinical trial studies the following conditions: Chronic Hepatitis C Infection, Genotype 1.
What interventions are being tested in trial NCT01194037?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a (DRUG), recombinant variant of interferon-alpha 2b (DRUG).
Who is sponsoring clinical trial NCT01194037?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01194037 being conducted?
This trial has 6 study locations across California, Florida, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.